Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

While Gilead’s Tecartus and Novartis’ Kymriah also boast approvals in ALL, Autolus’ new med boasts a unique edge as the only CAR-T that doesn’t come with an FDA requirement for a Risk Evaluation ...

Novartis previously signed an agreement with CellforCure in July to produce CAR-T cell therapies including Kymriah (tisagenlecleucel) – which was the first CAR-T cell therapy approved by the FDA ...

Novartis’ CAR-T therapy Kymriah will be available in the US to adults with relapsed large B-cell lymphoma – bringing the cell therapy into direct competition with Gilead’s rival at exactly ...

Senator asks Novartis to explain its payments to Cohen, noting FDA approval of cancer drug Novartis made $1.2 million in payments to Cohen's firm during the time that the FDA was deciding whether ...

LEGN)), and Novartis’ Kymriah. These therapies are individually approved for multiple myeloma, large B-cell lymphoma, and other blood cancers. The FDA specifically instructs the companies to ...

The focus of the probe may be Novartis AG’s Kymriah, RBC Capital Markets analysts led by Brian Abrahams said in a note to clients. The regulator’s adverse events database points to the therapy ...

The US regulatory body’s decision was based on the results of a Novartis-sponsored clinical trial, in which 52 of 63 patients (83%) who received the Kymriah treatment achieved remission from ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

LONDON — Novartis on Tuesday increased its earnings guidance for the third time this year, boosted by strong sales of its leading drugs. The company said it anticipates full-year operating ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...